Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

Alzheimer's disease (AD), is a progressive neurodegenerative disease that affects behavior,
thinking, learning, and memory in elderly individuals. AD occurs in two forms, early onset …

Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of
Alzheimer's disease (AD). Aβ exists as various species, including monomers, oligomers …

The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the
pathogenesis of Alzheimer's disease (AD) is substantial. Yet, only a few anti-amyloid agents …

Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing
aggregated Aβ from the brains of symptomatic patients can slow the progression of …

β-amyloid (Aβ)–dependent neuronal hyperactivity is believed to contribute to the circuit
dysfunction that characterizes the early stages of Alzheimer's disease (AD). Although …

The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …

Alzheimer's disease is a progressive neurodegenerative disease typically presenting with
symptoms of memory loss and cognitive decline. Existing theories for the causation of this …

Experimental models of Alzheimer's disease (AD) are critical to gaining a better
understanding of pathogenesis and to assess the potential of novel therapeutic approaches …

Background Synapse damage and loss are fundamental to the pathophysiology of
Alzheimer's disease (AD) and lead to reduced cognitive function. The goal of this review is to …